Article Contents
- 2023 (Vol.86)
- 2022 (Vol.85)
- 2021 (Vol.84)
- 2020 (Vol.83)
- 2019 (Vol.82)
- 2018 (Vol.81)
- 2017 (Vol.80)
- 2016 (Vol.79)
- 2015 (Vol.78)
- 2014 (Vol.76)
- 2013 (Vol.74)
- 2012 (Vol.72)
- 2011 (Vol.70)
- 2010 (Vol.68)
- 2009 (Vol.66)
- 2008 (Vol.64)
- 2007 (Vol.62)
- 2006 (Vol.60)
- 2005 (Vol.58)
- 2004 (Vol.56)
- 2003 (Vol.54)
- 2002 (Vol.52)
Systemic White Blood Cell Count as a Biomarker Associated with Severity of Chronic Obstructive Lung Disease
SONGPAMELA
- Downloaded
- Viewed
Abstract
Background: Chronic obstructive pulmonary disease (COPD), is a chronic inflammatory disorder. We evaluated whether white blood cell (WBC) count, is associated with the severity of COPD, independent of other inflammatory conditions, such as metabolic syndrome. Methods: The WBC counts were compared between 1227 COPD patients and 8679 non-COPD adults older than 40. The relationships between the WBC count, lung function, and symptoms score in COPD patients, were determined, using general linear regression analyses. Results: The WBC count was negatively associated with forced vital capacity (FVC, L), FVC (% predicted), forced expiry volume in one second (FEV1, L), and FEV1 (% predicted) in COPD patients. Additionally, the WBC count was independently associated with the quality of life measure, by EQ5D-index score. However, this relationship between WBC count, and disease severity, was not significant in current smokers, because of the confounding effect of smoking, on the WBC count. Conclusion: The WBC count is associated with current smoking status and COPD severity, and a risk factor for poor lung function, and quality of life, especially in non-currently smoking COPD patients. The WBC count can be used, as an easily measurable COPD biomarker.
- keywords
- Pulmonary Disease, Chronic Obstructive, Leukocyte Count, Respiratory Function Tests, Quality of Life
Reference
1. Roisin RR. Global strategy for the diagnosis, management and prevention of COPD. Updated 2016 [Internet]. Global Initiative for Chronic Obstructive; 2016 [cited 2016 Feb 10]. Available from: http://www.goldcopd.org.
2. Chung KF, Adcock IM. Multifaceted mechanisms in COPD:inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008;31:1334-56.
3. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
4. Mannino DM, Valvi D, Mullerova H, Tal-Singer R. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD 2012;9:359-66.
5. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
6. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF Jr, Lipinska I, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008;133:19-25.
7. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 2010;11:77.
8. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1065-72.
9. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12.
10. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85.
11. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:982-8.
12. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med 2012;186:11-6.
13. Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011;32:2365-75.
14. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
15. Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis 2005;58:230-42.
16. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
17. Wilke S, Janssen DJ, Wouters EF, Schols JM, Franssen FM, Spruit MA. Correlations between disease-specific and generic health status questionnaires in patients with advanced COPD: a one-year observational study. Health Qual Life Outcomes 2012;10:98.
18. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006;130:1117-28.
19. Canavan JL, Dilaver D, Clark AL, Jones SE, Nolan CM, Kon SS, et al. Clinical COPD Questionnaire in patients with chronic respiratory disease. Respirology 2014;19:1006-12.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
21. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14.
22. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483.
23. Fattouh M, Alkady O. Inflammatory biomarkers in chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc 2014;63:799-804.
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations